Matthew Sniegowski is an Ophthalmology physician. OpenAlex indexes 36 publications with 907 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11261 Nall Ave
Leawood, KS 662111669
Telephone
913-261-2020Provider last certified this registry record 18 Dec 2025.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ANI Pharmaceuticals, Inc.Program year20252 payments
- Bausch & Lomb Americas Inc.Program year20251 payment
- Globus Medical, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
75.2%Neuromuscular Blocker75.2%Onabotulinumtoxina100%Part B, office-administered≥19 patientsAnti-infectives
15.5%Macrolide15.5%Erythromycin100%Part D≥325 patientsSensory organs
6.7%Aminoglycoside Antibacterial5.7%Neomycin-Polymyxin-Dexameth83%Tobramycin-Dexamethasone17%Part D≥110 patientsCorticosteroid1.1%Prednisolone Acetate100%Part D≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab
Ophthalmic Plastic and Reconstructive Surgery
2022 - Thyroid Eye Disease.
PubMed
2022 - Specific location of ocular adnexal lymphoma and mortality: an international multicentre retrospective study
British Journal of Ophthalmology
2022 - Lymphoma of the Lacrimal Gland — An International Multicenter Retrospective Study
American Journal of Ophthalmology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”